Canada markets open in 32 minutes

Oncolytics Biotech Inc. (ONC.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
2.1100+0.0800 (+3.94%)
At close: 03:59PM EST

Oncolytics Biotech Inc.

1167 Kensington Crescent NW
Suite 210
Calgary, AB T2N 1X7
Canada
403 670 7377
http://www.oncolyticsbiotech.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees25

Key Executives

NameTitlePayExercisedYear Born
Dr. Matthew C. CoffeyPres, CEO & Director857.41kN/AN/A
Mr. Kirk J. Look C.A., CAChief Financial Officer600.26kN/AN/A
Dr. Thomas C. Heineman M.D., Ph.D.Global Head of Clinical Devel. & Operations601.96kN/AN/A
Mr. Andrew R. de GuttadauroGlobal Head of Bus. Devel. & Pres of Oncolytics Biotech (U.S.) Inc482.15kN/A1967
Ms. Allison Hagerman P.Eng., P.M.P.VP of Product Devel.317k41.9kN/A
Jon PattonDirector of Investor Relations & CommunicationN/AN/AN/A
Dr. Grey Wilkinson Ph.D.Scientist of Translational MedicineN/AN/AN/A
Mr. John Mark Lievonen B.B.A., F.C.A., FCA, FCPA, LLD, M.B.A.ConsultantN/AN/AN/A
Dr. Daniel Douglas Von Hoff FACP, M.D., F.A.C.P.ConsultantN/AN/A1948
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an immuno-oncology viral-agent for the treatment of solid tumors and hematological malignancies. The company has collaboration agreements with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone-receptor positive, human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Corporate Governance

Oncolytics Biotech Inc.’s ISS Governance QualityScore as of September 26, 2021 is 7. The pillar scores are Audit: 6; Board: 8; Shareholder Rights: 4; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.